David JD - Sio Gene CFO, CEO
| SIOXDelisted Stock | USD 0.40 0.01 2.56% |
Insider
David JD is CFO, CEO of Sio Gene Therapies
| Age | 69 |
| Phone | 877 746 4891 |
| Web | https://www.siogtx.com |
Sio Gene Management Efficiency
The company has return on total asset (ROA) of (0.2434) % which means that it has lost $0.2434 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.475) %, meaning that it created substantial loss on money invested by shareholders. Sio Gene's management efficiency ratios could be used to measure how well Sio Gene manages its routine affairs as well as how well it operates its assets and liabilities.Sio Gene Therapies currently holds 2.36 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sio Gene Therapies has a current ratio of 6.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Sio Gene's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| John MD | Vincerx Pharma | N/A | |
| W Vernon | Nuvation Bio | 65 | |
| Brian MD | Rezolute | 49 | |
| MBA CFA | Vaccinex | 50 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Calvin MD | Surrozen | N/A | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Maurice Zauderer | Vaccinex | 78 | |
| Edward DVM | SAB Biotherapeutics | N/A | |
| MBA MPH | Protara Therapeutics | 41 | |
| Justin Trojanowski | Tempest Therapeutics | 36 | |
| Kerry Wentworth | Nuvation Bio | 51 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| LLM JD | Rezolute | 63 | |
| DPHIL DPhil | CytomX Therapeutics | 57 | |
| MBA MD | Monopar Therapeutics | 38 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| AO FRACP | Assembly Biosciences | 65 | |
| Kristina Engeseth | Aligos Therapeutics | N/A | |
| Lucinda JD | Aligos Therapeutics | 52 | |
Management Performance
| Return On Equity | -0.47 | |||
| Return On Asset | -0.24 |
Sio Gene Therapies Management Team
Elected by the shareholders, the Sio Gene's board of directors comprises two types of representatives: Sio Gene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sio. The board's role is to monitor Sio Gene's management team and ensure that shareholders' interests are well served. Sio Gene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sio Gene's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Raquel Crystal, Head Operations | ||
| David JD, CFO, CEO | ||
| Guangping Gao, Chief Advisor |
Sio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sio Gene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | |||
| Return On Asset | -0.24 | |||
| Current Valuation | (23.36 M) | |||
| Shares Outstanding | 73.98 M | |||
| Shares Owned By Insiders | 25.30 % | |||
| Shares Owned By Institutions | 26.82 % | |||
| Number Of Shares Shorted | 71.39 K | |||
| Price To Book | 0.54 X | |||
| EBITDA | (70.94 M) | |||
| Net Income | (71.89 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Sio Stock
If you are still planning to invest in Sio Gene Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sio Gene's history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |